MK 2206: all 44 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryCompletedNCT01802320Phase 2Results posted
• Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast CancerTerminatedNCT01776008Phase 2Results posted
• Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With ChemotherapyCompletedNCT01658943Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaCompletedNCT01604772Phase 2Results posted
• Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or DabrafenibTerminatedNCT01519427Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT01481129Phase 2Results posted
• MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by SurgeryCompletedNCT01425879Phase 2Results posted
• Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01369849Phase 1/2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT01349933Phase 2Results posted
• MK-2206 and AZD6244 in Patients With Advanced Colorectal CarcinomaCompletedNCT01333475Phase 2Results posted
• MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast CancerTerminatedNCT01319539Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial CancerCompletedNCT01307631Phase 2Results posted
• Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedNCT01306045Phase 2Results posted
• MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride TherapyCompletedNCT01294306Phase 2Results posted
• A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT01283035Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Advanced Breast CancerCompletedNCT01277757Phase 2Results posted
• Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT01260701Phase 2Results posted
• Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaCompletedNCT01258998Phase 2Results posted
• AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT01253447Phase 2Results posted
• Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate CancerCompletedNCT01251861Phase 2Results posted
• BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01248247Phase 2Results posted
• A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)TerminatedNCT01243762Phase 1Results posted
• MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous TherapyTerminatedNCT01239355Phase 2Results posted
• Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerTerminatedNCT01239342Phase 2Results posted
• MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor MalignanciesCompletedNCT01235897Phase 1Results posted
• Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal CancerTerminatedNCT01186705Phase 2Results posted
• Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)CompletedNCT01169649Phase 2Results posted
• A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)CompletedNCT01021748Phase 1Results posted
• Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)CompletedNCT00670488Phase 1Results posted
• Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By SurgeryWithdrawnNCT01859182Phase 2
• Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT01783171Phase 1
• Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTerminatedNCT01705340Phase 1
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney CancerActive, not recruitingNCT01480154Phase 1
• Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell LymphomaTerminatedNCT01466868Phase 2
• MK-2206 in Recurrent Nasopharyngeal CarcinomaCompletedNCT01370070Phase 2
• Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)CompletedNCT01295632Phase 1
• Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerTerminatedNCT01281163Phase 1
• MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast CancerCompletedNCT01263145Phase 1
• MK-2206 for Recurrent Malignant GliomaWithdrawnNCT01249105Phase 2
• Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerCompletedNCT01245205Phase 1
• Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast CancerWithdrawnNCT01240941Phase 2
• MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
• Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)Status unknownNCT01147211Phase 1
• A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)CompletedNCT01071018Phase 1

← MK 2206 overview